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Abstract
Objective: To evaluate adjuvant chemotherapy use for Stage III colon cancer.
Methods: This analysis included 973 patients with surgically treated stage III colon cancer. Socioeconomic information from the 2000 
census was linked to patients’ residential census tracts. Vital status through 12/31/02 was obtained from medical records and linkage to 
state vital statistics files and the National Death Index.
Results: Adjuvant chemotherapy was received by 67%. Treatment varied by state of residence, with Colorado, Rhode Island and 
New York residents more likely to receive chemotherapy than Louisiana residents. Older age, increasing comorbidities, divorced/
widowed marital status, and residence in lower education areas or non-working class neighborhoods were associated with lower 
chemotherapy use. Survival varied by state but after adjustment for sex, sociodemographic and health factors, was significantly higher 
only for California and Rhode Island. Older age and lower educational attainment were associated with lower survival. Chemotherapy 
was protective for all comorbidity groups.
Conclusion: Although adjuvant chemotherapy for Stage III colon cancer improves survival, some patients did not receive standard of 
care, demonstrating the need for cancer treatment surveillance. Interstate differences likely resulted from differences in local practice 
patterns, acceptance of treatment, and access.
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Introduction
Colon  cancer,  exclusive  of  rectal  cancer,  killed 
approximately  45,000  people  in  the  U.S.  in 
20041  making  it  the  second  most  common  cause 
of  cancer  death  among  men  and  women  com-
bined. Although screening and early detection are 
the  best  way  to  prevent  death  from  this  disease, 
adjuvant chemotherapy (chemotherapy given after 
surgical management) has been shown to improve 
survival.  A  National  Institutes  of  Health  consen-
sus conference in 1990 addressed which colorectal 
cancer  patients  were  at  risk  for  recurrence  after 
surgery, and whether adjuvant chemotherapies were 
effective. Recommendations varied by stage, with a 
recommendation for chemotherapy after surgery for 
eligible patients with Stage III colon cancer without 
contraindications.2  However,  prior  studies  have 
suggested that many patients do not receive stage-
appropriate treatment.3
The Centers for Disease Control and Prevention’s 
National Program of Cancer Registries (CDC-NPCR) 
Patterns of Care (POC) study was organized as the 
result of two reports from the Institute of Medicine 
(IOM).4,5  The  National  Cancer  Policy  Board  of 
the IOM concluded that some individuals may not 
be  receiving  effective  treatment  for  cancer,  and 
recommended that data systems such as the NPCR be 
used to conduct surveillance of cancer treatment in 
the United States. Cancer registries routinely collect 
information on first course of treatment. However 
data  on  chemotherapy  may  be  missing,  particu-
larly if administered in outpatient facilities. CDC 
and state investigators collaborated to assess both 
quality of treatment data in state cancer registries, 
and  receipt  of  appropriate  treatment  by  cancer 
patients in those states. The POC study enabled a 
reabstraction of registry data on the characteristics 
and  treatment  of  localized  female  breast  cancer, 
regional colon cancer, and localized prostate can-
cer in the United States.6 For the first time, the POC 
study allowed a large-scale evaluation of data among 
several state population-based cancer registries sup-
ported by CDC-NPCR. The objective of this study 
was to evaluate the use of adjuvant chemotherapy 
for surgically treated patients diagnosed with Stage 
III colon cancer resident in seven states covered by 
the CDC-NPCR program as part of the larger study 
of patterns of care.
Methods
Administered by CDC, NPCR collects data on cancer 
incidence through central cancer registries in 45 states, 
the District of Columbia, Puerto Rico, the Republic 
of Palau and the Virgin Islands. In this study, staff 
from  seven  population-based  state  cancer  registries 
(California, Colorado, Illinois, Louisiana, New York, 
South Carolina, Rhode Island) collected supplemental 
treatment data for a random sample of cancer patients 
diagnosed in 1997.7 Patients included in the current 
analysis  were  those  diagnosed  with  a  first  primary 
Stage III colon cancer (ICD-O site codes C18.0–18.9), 
defined  as American  Joint  Commission  on  Cancer 
pathology stage at diagnosis of 3, 3A, 3B, 3C and Sum-
mary Stage 3 or 4 according to SEER Summary Stage 
1977.8 Only patients with adenocarcinoma or adeno-
squamous carcinoma who received surgical treatment 
for their colon cancer were included. Patients diag-
nosed with a subsequent cancer within four months of 
their colon cancer diagnosis, and patients whose date 
of death or last contact was within 30 days of surgery, 
were excluded.
Trained abstractors gathered information on treat-
ment and other factors from patient medical records, 
including hospital charts and records from physician 
offices, ambulatory surgery and radiation therapy faci-
lities. ICD-9-CM codes recorded in medical records 
were extracted to assess the presence of comorbid 
illness, which would influence receipt of treatment. 
Comorbid  illness  burden  was  assessed  using  the 
Charlson comorbidity index, which yields a score based 
on the number of conditions present, and the weight for 
that condition. Codes for the 17 conditions that make up 
the Charlson index were consolidated into a summary 
Charlson measure.9 Race and ethnicity information was 
combined to create four groups: Hispanic, non-Hispanic 
white, non-Hispanic black, and non-Hispanic other (incl-
uding  Asian/Pacific  Islander)  or  unknown.  Patients 
were categorized as non-Hispanic unless there was 
evidence to the contrary.
Each patient’s address at the time of diagnosis was 
geocoded to the appropriate census tract within the 
state  of  residence.  Information  on  socioeconomic 
status (poverty, education and occupation) and urban 
vs. rural residence from the 2000 census was assigned 
to each census tract and linked to the patient’s census 
tract of residence. Patients residing in census tracts 
where fewer than 25% of adults had a high school Adjuvant chemotherapy for patients with stage iii colon cancer
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education  were  classified  as  of  lower  education 
attainment; those residing in census tracts where at 
least 66% of adults were in a working class occupation 
were classified as working class; and those residing in 
census tracts where at least 20% of residents lived 
below the 2000 Federal Poverty Level were classified 
as in poverty.10
Insurance  status  was  determined  from  medical 
records. Private insurance included those with either 
private  insurance  or  Medicare  with  a  supplement. 
Public  insurance  included  those  with  Medicare, 
Medicaid or welfare, or other federally funded health 
insurance. Vital status as of 12/31/02 was obtained 
from medical records and physician offices, and was 
enhanced by linking to state vital statistics files and to 
the National Death Index.
Analysis
We examined the proportions of patients receiving 
adjuvant  chemotherapy  by  sociodemographic  and 
health factors for the entire sample and after stratifying 
by sex. Fifty-eight patients who were missing infor-
mation about receipt of chemotherapy were excluded 
from the analysis of treatment receipt. In addition, 
we used multivariable logistic regression modeling 
to examine the crude and adjusted odds ratios with 
95% confidence intervals of receiving adjuvant che-
motherapy. Odds ratios were adjusted for age at diagn-
osis, sex, race/ethnicity, marital status, registry, health 
insurance, urban-rural residence, poverty, education, 
working class status, and Charlson comorbidity score. 
Model goodness of fit was tested with the Hosmer-
Lemeshow test. Reference categories were generally 
chosen to be those with the greatest numbers, except 
where selected to facilitate comparisons with other 
studies.
Finally,  we  examined  survival  from  diagnosis 
through December 31, 2002. First, we estimated the 
proportion of patients surviving 5 years by receipt 
of chemotherapy, sex, sociodemographic and health 
factors. In addition, we used Cox proportional hazards 
models to estimate crude and adjusted hazards ratios 
with  95%  confidence  intervals,  adjusting  for  all 
factors. We considered death due to any cause as an 
event. Because patients who received chemotherapy 
survived at least long enough to receive treatment, 
a  time-varying  covariate  for  receipt  of  adjuvant 
chemotherapy was included in the models to reduce 
potential  bias.  Time-varying  covariates  also  were 
used  to  test  the  proportional  hazards  assumption, 
which was violated for age at diagnosis. Therefore a 
time-varying covariate for age was kept in the model. 
We also examined an interaction between receiving 
adjuvant chemotherapy and comorbidity status. For 
dates, missing information about day of the month 
(n = 27) was coded to 15 for February and to 16 for 
all other months. Missing information about month 
(n = 1) was left as missing. SAS statistical software 
(version 9.1, SAS Institute, Cary, NC) was used in all 
analyses. P values  0.05 were considered statisti-
cally significant.
Results
A total of 1066 patients with Stage III colon cancer 
were identified. Patients with histologic types other 
than adenocarcinoma or adenosquamous carcinoma 
were excluded (n = 5) as well as one patient who did 
not receive surgical treatment, 20 patients diagnosed 
with a subsequent cancer within four months of their 
colon cancer diagnosis, and 67 patients whose date of 
death or last contact was within 30 days of surgery. 
Our final sample included 973 patients. Character-
istics of the study population are shown in Table 1. 
Slightly more than half (53%) were female and the 
majority of patients were non-Hispanic white (76%), 
aged  65  or  older  (61%),  and  lived  in  urban  areas 
(67%).  Most  had  private  insurance  (69%)  and  the 
majority had no indication of comorbid illness in the 
medical record (75%).
Patients were classified as being treated if information 
in  the  medical  record  indicated  they  had  received 
any chemotherapy. Table 2 shows the unadjusted 
percent distributions of receipt of chemotherapy by 
sociodemographic and health factors. A total of 67% 
of eligible patients had a record of receipt of adjuvant 
chemotherapy. Patients under age 50 had the highest 
proportion of treatment (86%) and this declined to 
41% among patients aged 75 and older. Differences in 
treatment by race group were non-significant; receipt 
of adjuvant chemotherapy was slightly higher among 
males than females in all race groups except non-
Hispanic blacks where women had a higher rate of 
treatment. The proportion of patients treated was higher 
for married patients. The proportion of patients who 
received adjuvant chemotherapy varied by their state 
of residence, from 59% to 73%, although differences Cress et al
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Table 1. Distribution of patients with stage iii colon cancer by sex, sociodemographic and health factors in selected areas 
of the United states, 1997 (n = 973).
Total n (%) Males n (%) Females n (%)
All cancers 973 (100) 461 (100) 512 (100)
Age at diagnosis (y)
  50 113 (12) 61 (13) 52 (10)
  50–64 259 (27) 132 (29) 127 (25)
  65–74 267 (27) 132 (29) 135 (26)
  75 334 (34) 136 (30) 198 (39)
race/ethnicity
  hispanic 47 (5) 24 (5) 23 (4)
  non-hispanic White 736 (76) 349 (76) 387 (76)
  non-hispanic Black 164 (17) 73 (16) 91 (18)
  Other/unknown 26 (3) 15 (3) 11 (2)
Marital status
  Married 558 (57) 326 (71) 232 (45)
  single 89 (9) 46 (10) 43 (8)
  Othera 304 (31) 80 (17) 224 (44)
  Unknown 22 (2) 9 (2) 13 (3)
registry
  Colorado 157 (16) 85 (18) 72 (14)
  Louisiana 197 (20) 93 (20) 104 (20)
  illinois 163 (17) 83 (18) 80 (16)
  California 138 (14) 61 (13) 77 (15)
  rhode island 80 (8) 28 (6) 52 (10)
  south Carolina 104 (11) 39 (8) 65 (13)
  new York 134 (14) 72 (16) 62 (12)
health insuranceb
  Private 676 (69) 319 (69) 357 (70)
  Public 198 (20) 92 (20) 106 (21)
  none 33 (3) 19 (4) 14 (3)
  Other/unknown 66 (7) 31 (7) 35 (7)
residencec
  100% Urban 654 (67) 306 (66) 348 (68)
  Urban-rural mix 254 (26) 117 (25) 137 (27)
  100% rural 63 (6) 37 (8) 26 (5)
  Missing 2 (0.2) 1 (0.2) 1 (0.2)
Povertyc,d
  in Poverty 273 (28) 112 (24) 161 (31)
  not in Poverty 698 (72) 348 (75) 350 (68)
  Missing 2 (0.2) 1 (0.2) 1 (0.2)
educationc,e
    higher educational attainment 679 (70) 324 (70) 355 (69)
  Lower educational attainment 292 (30) 136 (30) 156 (30)
  Missing 2 (0.2) 1 (0.2) 1 (0.2)
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Table 1. (Continued)
Total n (%) Males n (%) Females n (%)
Working classc,f
  non-working class 465 (48) 218 (47) 247 (48)
  Working class 506 (52) 242 (52) 264 (52)
  Missing 2 (0.2) 1 (0.2) 1 (0.2)
Comorbiditiesg
  0 734 (75) 341 (74) 394 (77)
  1 181 (19) 92 (20) 89 (17)
  2+ 58 (6) 29 (6) 29 (6)
aOther includes divorced, separated, and widowed.
bPrivate insurance includes those with private insurance or Medicare with supplement. Public insurance includes those with Medicare, Medicaid or welfare, 
or other federally funded health insurance.
cData derived from the 2000 U.s. Census according to the census tract of the patient’s address.
din poverty includes adults residing in census tracts where at least 20% of residents lived below the 2000 Federal Poverty Level.
ehigher educational attainment includes adults residing in areas where 25% of adults have less than a high school education. Lower educational 
attainment includes adults residing in areas where 25% of adults have less than a high school education.
fnon-working class includes adults residing in areas where 66% of adults are in a working class occupation. Working class includes adults residing in 
areas where 66% of adults are in a working class occupation.
gDetermined by Charlson score.
were not statistically significant. Patients with public 
insurance had the lowest likelihood of treatment, while 
those with no known health insurance had a higher 
proportion of treatment, although only a small number 
of patients were included in this category. Patients 
residing in rural communities had a non-significantly 
higher likelihood of treatment, as did patients residing 
in census tracts where a higher proportion of residents 
were educated. Patients with two or more comorbid 
illnesses recorded in their medical records were less 
likely to have received adjuvant treatment than those 
with no comorbid illness.
Crude and adjusted odds ratios for receipt of adju-
vant chemotherapy in this population are shown in 
Table 3. After adjustment for other variables, state 
of residence was the strongest predictor of receipt of 
adjuvant treatment, and patients residing in three states 
(Colorado, Rhode Island, New York) were about twice 
as likely as those in the reference state (Louisiana) to 
have received treatment. Age also was a powerful pre-
dictor of receipt of adjuvant treatment, and patients 
aged 75 and older were only 24% as likely to have 
received this treatment compared to those aged 65 to 74. 
Patients with two or more comorbid illnesses were 
about one-third as likely as those with no comorbidity 
to  have  received  treatment.  Divorced  or  widowed 
patients were about half as likely as married patients 
to  have  received  treatment.  Patients  who  lived  in 
census tracts with lower educational attainment were 
less likely to have received adjuvant therapy, however 
those  living  in  working  class  neighborhoods  were 
more likely to have received treatment after adjusting 
for other factors, and census tract level of poverty did 
not  affect  probability  of  treatment.  Race/ethnicity, 
gender,  urban/rural  residence,  and  health  insurance 
did not have a statistically significant effect on treat-
ment after adjustment for other variables.
Five year survival rates and crude and adjusted 
hazard  ratios  are  shown  in  Table  4.  Eighty-nine 
patients were missing information for the time-varying 
covariate  or  receipt  of  adjuvant  chemotherapy  and 
were  excluded  from  all  survival  analyses.  One 
additional individual was missing information about 
date of diagnosis, and therefore survival time could not 
be calculated. Therefore, data for these analyses were 
available from 883 patients. Patients aged 75 and 
older had a substantially higher risk of death from any 
cause in five years, and men had a higher risk of dying 
than did women (p = 0.06). Formerly married patients 
had a higher risk of death but this was not statistically 
significant after adjustment for age and other factors. 
Five year survival rates varied by state of residence, 
from 45% to 63%, but the hazard ratio was statisti-
cally significantly lower (survival significantly higher) 
only for California and Rhode Island after adjustment 
for other factors. Patients with public insurance or Cress et al
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Table 2. Proportion of patients with stage iii colon cancer with known treatment statusa receiving adjuvant chemotherapy, 
by sex, sociodemographic and health factors in selected areas of the United states, 1997 (n = 915).
number who received adjuvant chemotherapy
Total 
n
Males and   
Females  
n (%)
p Males 
n (%)
p Females 
n (%)
p
All cancers 915a 614 (67) 297 (69) 317 (65)
Age at diagnosis (y) 0.0001 0.0001 0.0001
  50 111 95 (86) 52 (85) 43 (86)
  50–64 246 204 (83) 102 (82) 102 (84)
  65–74 248 187 (75) 87 (73) 100 (78)
  75 310 128 (41) 56 (44) 72 (39)
race/ethnicity 0.94 0.46 0.54
  hispanic 43 28 (65) 16 (76) 12 (55)
  non-hispanic White 696 470 (68) 230 (70) 240 (65)
  non-hispanic Black 152 101 (66) 42 (62) 59 (70)
  Other/unknown 24 15 (63) 9 (64) 6 (60)
Marital status 0.0001 0.0001 0.001
  Married 530 395 (75) 229 (75) 166 (74)
  single 86 56 (65) 31 (69) 25 (61)
  Formerly marriedb 282 153 (54) 34 (47) 119 (57)
  Unknown 17 10 (59) 3 (50) 7 (64)
registry 0.07 0.44 0.12
  Colorado 151 109 (72) 62 (77) 47 (67)
  Louisiana 187 111 (59) 56 (62) 55 (57)
  illinois 156 102 (65) 49 (64) 53 (67)
  California 130 82 (63) 41 (71) 41 (57)
  rhode island 76 55 (72) 19 (70) 36 (73)
  south Carolina 94 69 (73) 23 (70) 46 (75)
  new York 121 86 (71) 47 (73) 39 (68)
health insurancec 0.001 0.02 0.04
  Private 633 443 (70) 216 (72) 227 (68)
  Public 190 107 (56) 51 (59) 56 (54)
  none 31 26 (84) 15 (83) 11 (85)
  Other/unknown 61 38 (62) 15 (56) 23 (68)
residenced 0.20 0.42 0.42
  100% Urban 614 409 (67) 192 (68) 217 (66)
  Urban-rural mix 237 156 (66) 76 (70) 80 (63)
  100% rural 62 48 (77) 29 (78) 19 (76)
Povertyd,e 0.41 0.10 0.67
  in Poverty 258 168 (65) 66 (63) 102 (67)
  not in Poverty 655 445 (68) 231 (71) 214 (65)
educationd,f 0.009 0.02 0.15
    higher educational 
attainment
639 446 (70) 219 (73) 227 (67)
    Lower educational 
attainment
274 167 (61) 78 (61) 89 (61)
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Table 2. (Continued)
number who received adjuvant chemotherapy
Total 
n
Males and   
females  
n (%)
p Males 
n (%)
p Females 
n (%)
p
Working classd,g 0.97 0.36 0.43
  non-working class 436 293 (67) 147 (71) 146 (63)
  Working class 477 320 (67) 150 (67) 170 (67)
Comorbiditiesh 0.0001 0.001 0.002
  0 689 488 (71) 233 (74) 255 (68)
  1 173 105 (61) 52 (60) 53 (62)
  2+ 53 21 (40) 12 (44) 9 (35)
a58 individuals missing information about receipt of adjuvant chemotherapy, 2 individuals missing information about residence, poverty, education and 
working class.
bFormerly married includes divorced, separated, and widowed.
cPrivate insurance includes those with private insurance or Medicare with supplement. Public insurance includes those with Medicare, Medicaid or welfare, 
or other federally funded health insurance.
dData derived from the 2000 U.s. Census according to the census tract of the patient’s address.
ein poverty includes adults residing in census tracts where at least 20% of residents lived below the 2000 Federal Poverty Level.
fhigher educational attainment includes adults residing in areas where 25% of adults have less than a high school education. Lower educational 
attainment includes adults residing in areas where 25% of adults have less than a high school education.
gnon-working class includes adults residing in areas where 66% of adults are in a working class occupation. Working class includes adults residing in 
areas where 66% of adults are in a working class occupation.
hDetermined by Charlson score.
without  insurance  had  a  higher  risk  of  death  than 
those with private insurance, but again this result was 
not statistically significant after adjustment. Patients 
with lower educational attainment also had a higher 
risk  of  death  than  those  with  higher  educational 
attainment.  Crude  hazard  ratios  show  that  patients 
with any comorbid condition were more likely to die 
than those with no comorbid illnesses, and those with 
two or more comorbid illnesses were approximately 
twice as likely to die. Unadjusted findings indicate 
that  almost  twice  as  many  patients  who  received 
adjuvant  chemotherapy  survived  five  years  (61% 
versus 33%). In multivariate analysis, a statistically 
significant interaction was found between receipt of 
adjuvant therapy and comorbidity status (p  0.025). 
Receiving chemotherapy was protective in all comor-
bidity groups, with the strongest effect among patients 
with  a  Charlson  score  of  one.  Among  those  who 
received chemotherapy, increasing comorbid illness 
burden was not associated with significantly lower 
survival. However among patients who did not receive 
chemotherapy, patients with comorbid illnesses had 
lower survival than patients with no comorbidities. 
No  statistically  significant  differences  in  survival 
were  observed  for  race,  urban/rural  residence,  or 
census based poverty status.
Discussion
Despite  the  powerful  evidence  that  chemotherapy 
after surgery for Stage III colon cancer can improve 
survival, results of this study confirm previous stud-
ies that suggested that some groups of patients do 
not receive standard of care for this disease. Similar 
to other studies, age, marital status and comorbidity 
were major predictors of receipt of chemotherapy.11 
For some individuals, adjuvant chemotherapy may 
not have been given due to contraindications from 
concurrent medical conditions. Our survival model 
suggested that adjuvant chemotherapy was protective 
among patients with and without comorbidities, and 
therefore seemed to suggest that, at least for some 
patients with higher comorbid illness burdens, adju-
vant treatment can be protective. However, we did not 
have detailed information about severity of comorbid 
conditions within the categories used in our analysis 
to examine this further.
Geographic  differences  by  state  persisted  after 
adjustment for other factors, and have not been studied Cress et al
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Table 3. Crude and adjusted odds ratios for receipt of adjuvant chemotherapy for stage iii colon cancer, by sociodemographic 
and health factors in selected areas of the United states, 1997.
crude OR (95% cI) 
(n = 915a)
Model 1b OR (95% cI) 
(n = 915a)
Model 2b OR (95% cI) 
(n = 913a)
Age at diagnosis (y)
  50 1.94j (1.06–3.54) 1.95j (1.06–3.58) 1.68 (0.88–3.21)
  50–64 1.58j (1.02–2.46) 1.60j (1.03–2.49) 1.48 (0.93–2.37)
  65–74 1.00 1.00 1.00
  75 0.23j (0.16–0.334) 0.22j (0.15–0.32) 0.24j (0.16–0.35)
sex
  Male 1.18 (0.90–1.56) 1.01 (0.74–1.37) 0.91 (0.65–1.27)
  Female 1.00 1.00 1.00
race/ethnicity
  hispanic 0.90 (0.47–1.71) 0.73 (0.36–1.47) 0.76 (0.36–1.61)
  non-hispanic White 1.00 1.00 1.00
  non-hispanic Black 0.95 (0.66–1.38) 0.73 (0.49–1.10) 1.06 (0.66–1.72)
  Other/unknown 0.80 (0.35–1.86) 0.63 (0.25–1.57) 0.85 (0.32–2.23)
Marital status
  Married 1.00 1.00 1.00
  single 0.64 (0.39–1.04) 0.61 (0.36–1.05) 0.60 (0.34–1.04)
  Formerly marriedc 0.41j (0.30–0.55) 0.63j (0.44–0.91) 0.59j (0.41–0.86)
  Unknown 0.49 (0.18–1.31) 0.56 (0.19–1.64) 0.48 (0.16–1.43)
registry
  Colorado 1.78j (1.12–2.82) 1.99j (1.18–3.37) 1.92j (1.10–3.36)
  Louisiana 1.00 1.00 1.00
  illinois 1.29 (0.83–2.01) 1.33 (0.82–2.17) 1.24 (0.73–2.09)
  California 1.17 (0.74–1.85) 1.19 (0.70–2.03) 1.41 (0.80–2.49)
  rhode island 1.79j (1.00–3.21) 2.20j (1.15–4.21) 2.57j (1.28–5.18)
  south Carolina 1.89j (1.10–3.25) 1.86j (1.02–3.39) 1.60 (0.81–3.15)
  new York 1.68j (1.03–2.75) 1.88j (1.09–3.26) 2.23j (1.23–4.04)
health insuranced
  Private 1.00 1.00 1.00
  Public 0.55j (0.40–0.77) 0.71 (0.49–1.02) 0.73 (0.49–1.07)
  none 2.23 (0.84–5.90) 0.98 (0.36–2.66) 1.05 (0.38–2.95)
  Other/unknown 0.71 (0.41–1.22) 0.57 (0.31–1.05) 0.59 (0.32–1.11)
residencee
  100% Urban 1.00 1.00 1.00
  Urban-rural mix 0.97 (0.70–1.33) 0.90 (0.63–1.27) 0.86 (0.59–1.26)
  100% rural 1.72 (0.93–3.19) 1.64 (0.84–3.22) 1.63 (0.79–3.35)
Povertye,f
  in Poverty 0.88 (0.65–1.19) 1.05 (0.74–1.50) 1.25 (0.79–1.99)
  not in Poverty 1.00 1.00 1.00
educatione,g
  higher educational attainment 1.00 1.00 1.00
  Lower educational attainment 0.68j (0.50–0.91) 0.74 (0.52–1.04) 0.61j (0.38–0.99)
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Table 3. (Continued)
crude OR (95% cI) 
(n = 915a)
Model 1b OR (95% cI) 
(n = 915a)
Model 2b OR (95% cI) 
(n = 913a)
Working classe,h
  non-working class 1.00 1.00 1.00
  Working class 1.00 (0.75–1.31) 1.14 (0.84–1.56) 1.55j (1.04–2.32)
Comorbiditiesi
  0 1.00 1.00 1.00
  1 0.64j (0.45–0.90) 0.81 (0.56–1.19) 0.79 (0.53–1.17)
  2+ 0.27j (0.15–0.48) 0.42j (0.22–0.79) 0.36j (0.19–0.70)
a58 individuals missing information about receipt of adjuvant chemotherapy. An additional 2 were missing information about urban residence, poverty, 
education and working class.
bModel 1 adjusted for age, sex, and race/ethnicity. Model 2 adjusted for all factors in the table.
cFormerly married includes divorced, separated, and widowed.
dPrivate insurance includes those with private insurance or Medicare with supplement. Public insurance includes those with Medicare, Medicaid or welfare, 
or other federally funded health insurance.
eData derived from the 2000 U.s. Census according to the census tract of the patient’s address.
fin poverty includes adults residing in census tracts where at least 20% of residents lived below the 2000 Federal Poverty Level.
ghigher educational attainment includes adults residing in areas where 25% of adults have less than a high school education. Lower educational 
attainment includes adults residing in areas where 25% of adults have less than a high school education.
hnon-working class includes adults residing in areas where 66% of adults are in a working class occupation. Working class includes adults residing in 
areas where 66% of adults are in a working class occupation.
iDetermined by Charlson score.
jp  0.05
as  extensively.  Interstate  differences  in  receipt  of 
treatment are likely a result of local practice patterns, 
lack of uniform acceptance of this treatment, and lack 
of access to treatment facilities. Regional differences 
in receipt of treatment also were seen in an earlier 
California study,11 as well as variation by hospital. In a 
survey of physicians, the most common reasons cited 
for not providing adjuvant chemotherapy for Stage III 
colon cancer were patient refusal, comorbid illness, and 
lack of clinical indication.11 Despite NIH recommen-
dations, over 20% of physicians reported that adju-
vant chemotherapy was not clinically indicated for 
their Stage III colon cancer patients.11 Interestingly, 
interstate differences in receipt of chemotherapy did 
not appear to correlate with interstate differences in 
survival, and it is likely that other factors are involved. 
This may be attributable in part to differences by state 
in the number of cases excluded from the survival 
analysis. Survival after diagnosis for patients in this 
study was influenced by age, comorbid illness, and 
receipt of chemotherapy.
Receipt of adjuvant treatment for patients in NPCR 
states appeared to be slightly, although not substan-
tially, lower than for patients in areas covered by the 
National Cancer Institute’s Surveillance, Epidemiol-
ogy and End Results (SEER) program. Results from 
SEER Patterns of Care studies reported that use of 
adjuvant  chemotherapy  for  Stage  III  colon  cancer 
increased  between  1989  and  1990  when  the  NIH 
consensus  conference  was  held,  and  has  remained 
relatively stable since 1990.12 Receipt of chemotherapy 
in 1995 by patients with Stage III colon cancer in the 
SEER study was 90% for patients aged 55 or younger. 
This is slightly higher than the 86% of patients aged 
50 or younger in the current study diagnosed in 1997. 
There  is  some  evidence  that  patients  residing  in 
SEER areas are somewhat more affluent than other 
areas of the U.S,13 and they may have greater access 
to high quality cancer care. Receipt of treatment for 
older patients in the current study was comparable to 
that for similarly aged patients studied using linked 
SEER-Medicare  data.  Treatment  rates  for  patients 
diagnosed with Stage III colon cancer between 1991 
and 1996 and identified through the SEER program 
were 78% for those aged 65 to 69, and 74% for those 
aged  70–74,  similar  to  the  75%  for  patients  aged 
65–74 in the current study diagnosed in 1997.14
Patients  residing  in  neighborhoods  with  less 
education were less likely to have received adjuvant 
chemotherapy, although residence in poor neighbor-
hoods did not have a statistically significant effect 
after adjustment for other factors. Patients residing in Cress et al
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Table  4.  Five-year  survival  and  crude  and  adjusted  hazard  ratios  for  patients  with  stage  iii  colon  cancer  by  sex, 
sociodemographic and health factors in selected areas of the United states, 1997 (n = 883a).
5 yr survival 
(%)
crude hazard 
Ratio (95% cI)
Adjusteda  
HR (95% cI) n = 881
All cases 51.2
Age at diagnosis (y)
  50 61.8 0.73 (0.51–1.05)
  50–64 59.5 0.79 (0.60–1.04)
  65–74 53.1 1.00
  75 39.2 1.58i (1.25–1.99)
sex
  Male 48.1 1.18 (0.98–1.42) 1.21 (0.99–1.47)
  Female 53.9 1.00 1.00
race/ethnicity
  hispanic 47.5 1.11 (0.71–1.72) 1.07 (0.67–1.71)
  non-hispanic White 51.7 1.00 1.00
  non-hispanic Black 49.6 1.04 (0.81–1.34) 0.90 (0.68–1.21)
  Other/unknown 41.9 1.16 (0.67–2.02) 1.11 (0.62–2.00)
Marital status
  Married 53.8 1.00 1.00
  single 49.5 1.19 (0.85–1.65) 1.09 (0.77–1.56)
  Formerly marriedb 45.0 1.40i (1.14–1.71) 1.22 (0.97–1.52)
  Unknown 64.2 0.66 (0.30–1.49) 0.67 (0.29–1.55)
registry
  Colorado 46.6 0.98 (0.74–1.32) 1.30 (0.93–1.81)
  Louisiana 45.0 1.00 1.00
  illinois 48.2 0.87 (0.64–1.17) 0.94 (0.68–1.31)
  California 62.5 0.61i (0.44–0.87) 0.62i (0.42–0.90)
  rhode island 62.6 0.59i (0.39–0.89) 0.62i (0.40–0.97)
  south Carolina 46.9 0.85 (0.59–1.22) 1.01 (0.66–1.54)
  new York 49.1 0.92 (0.68–1.26) 1.04 (0.74–1.47)
health insurancec
  Private 54.5 1.00 1.00
  Public 42.4 1.44i (1.16–1.80) 1.14 (0.90–1.44)
  none 48.3 1.05 (0.63–1.77) 1.37 (0.79–2.38)
  Other/unknown 46.1 1.23 (0.85–1.77) 1.31 (0.89–1.92)
residenced
  100% Urban 51.7 1.00 1.00
  Urban-rural mix 52.0 1.04 (0.84–1.29) 1.00 (0.80–1.26)
  100% rural 41.4 1.22 (0.84–1.75) 1.15 (0.78–1.70)
Povertyd,e
  in Poverty 49.9 1.06 (0.86–1.30) 0.92 (0.70–1.22)
  not in Poverty 51.8 1.00 1.00
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Table 4. (Continued)
5 yr survival 
(%)
crude hazard 
Ratio (95% cI)
Adjusteda  
HR (95% cI) n = 881
educationd,f
    higher educational attainment 53.5 1.00 1.00
    Lower educational attainment 45.7 1.26i (1.04–1.54) 1.34i (1.00–1.79)
Working classd,g
  non-working class 53.5 1.00 1.00
  Working class 49.0 1.15 (0.96–1.39) 0.96 (0.75–1.22)
Comorbiditiesh
  0 55.6 1.00 1.00j
  1 40.0 1.58i (1.26–1.99)
      Among those who received 
chemotherapy
1.08 (0.76–1.54)
      Among those who did not 
receive chemotherapy
2.08 (1.50–2.87)
  2+ 26.0 2.26i (1.62–3.17)
      Among those who received 
chemotherapy
1.62 (0.84–3.11)
      Among those who did not 
receive chemotherapy
2.03 (1.32–3.12)
Adjuvant chemotherapy
  no 32.5 1.00 1.00j
  Yes 60.8 0.41i (0.34–0.50)
      Among those with no 
comorbidities
0.57 (0.44–0.73)
      Among those with 1 
comorbidity
0.30 (0.19–0.45)
      Among those with 2+ 
comorbidities
0.45 (0.22–0.95)
aAdjusted for age and factors in the table. 90 individuals were missing information about whether or not they received chemotherapy or the time interval 
between diagnosis to receipt of chemotherapy. An additional 2 individuals were missing information about poverty, education, urban residence and working 
class. Therefore for those factors, n = 881.
bFormerly married includes divorced, separated, and widowed.
cPrivate insurance includes those with private insurance or Medicare with supplement. Public insurance includes those with Medicare, Medicaid or welfare, 
or other federally funded health insurance.
dData derived from the 2000 U.s. Census according to the census tract of the patient’s address.
ein poverty includes adults residing in census tracts where at least 20% of residents lived below the 2000 Federal Poverty Level.
fhigher educational attainment includes adults residing in areas where 25% of adults have less than a high school education. Lower educational 
attainment includes adults residing in areas where 25% of adults have less than a high school education.
gnon-working class includes adults residing in areas where 66% of adults are in a working class occupation. Working class includes adults residing in 
areas where 66% of adults are in a working class occupation.
hDetermined by Charlson score.
ip  0.05
jinteraction between comorbidity and adjuvant chemotherapy use significant, p  0.05.
rural areas of the U.S. were not substantially less likely 
to  have  received  treatment.  Adjuvant  chemothe-
rapy is usually administered in outpatient treatment 
facilities and does not require the access to special-
ized treatment facilities required by adjuvant radiation 
treatment. Type of health insurance did not have a 
significant effect on receipt of treatment after adjust-
ment for other factors, and did not influence survival. 
The majority of patients in the analysis were aged 65 
or older and would have been covered by Medicare.Cress et al
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Our  study  was  subject  to  several  limitations. 
First, data were collected from seven states and are 
therefore not necessarily generalizable to all states. 
Moreover, data for this study were collected five years 
after the cancer diagnosis year, and therefore some 
patient  records  were  not  retrievable.  Additionally, 
completeness  of  chemotherapy  data  may  vary  by 
registry. Our measures of socioeconomic status were 
derived  from  Census  data  and  were  therefore  not 
individual-level data. Furthermore, we only collected 
comorbidities that had been coded on the face sheets 
of patients’ medical records. Therefore, comorbidi-
ties may have been underreported. Finally, we were 
unable to examine cause-specific mortality in addition 
to overall mortality.
The CDC-NPCR Patterns of Care study follows 
the National Cancer Policy Board recommendation 
that  data  systems  such  as  the  NPCR  be  used  to 
conduct  surveillance  of  cancer  treatment  in  the 
United States. The study demonstrated the need for 
surveillance of cancer treatment across the U.S. by 
confirming gaps in treatment for some groups. This 
study also documented the substantial challenges to 
treatment surveillance using cancer registry treatment 
data. Analysis of quality of registry treatment data for 
patients in this study showed that only about 71% of 
chemotherapy received by colon cancer patients was 
captured  by  cancer  registries  through  routine  data 
collection.6 Use of registries for treatment surveillance 
will continue to require that treatment contained in 
the NPCR registries, as in SEER registries, be supple-
mented with data collection in physician offices and 
other treatment facilities.
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